Literature DB >> 19629392

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.

Maria Alessandra Santucci1, Manuela Mancini, Valentina Corradi, Ilaria Lacobucci, Giovanni Martinelli, Maurizio Botta, Silvia Schenone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19629392     DOI： 10.1007/s10637-009-9294-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  7 in total

1.  Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.

Authors:  Fabrizio Manetti; Chiara Brullo; Matteo Magnani; Francesca Mosci; Beatrice Chelli; Emmanuele Crespan; Silvia Schenone; Antonella Naldini; Olga Bruno; Maria Letizia Trincavelli; Giovanni Maga; Fabio Carraro; Claudia Martini; Francesco Bondavalli; Maurizio Botta
Journal:  J Med Chem       Date:  2008-02-08       Impact factor: 7.446

2.  C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Authors:  Maria Alessandra Santucci; Valentina Corradi; Manuela Mancini; Fabrizio Manetti; Marco Radi; Silvia Schenone; Maurizio Botta
Journal:  ChemMedChem       Date:  2009-01       Impact factor: 3.466

Review 3.  Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

5.  P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors.

Authors:  Gianluca Brusa; Elisa Zuffa; Manuela Mancini; Michela Benvenuti; Natalia Calonghi; Enza Barbieri; Maria Alessandra Santucci
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.